PMID- 34287830
OWN - NLM
STAT- MEDLINE
DCOM- 20220421
LR  - 20230502
IS  - 1365-4632 (Electronic)
IS  - 0011-9059 (Print)
IS  - 0011-9059 (Linking)
VI  - 61
IP  - 5
DP  - 2022 May
TI  - Merkel cell carcinoma: treatment and outcomes over a 10-year period at a 
      high-volume academic center.
PG  - 558-563
LID - 10.1111/ijd.15759 [doi]
AB  - BACKGROUND: Merkel cell carcinoma (MCC) is a rare, highly aggressive malignancy 
      which lacks high-level evidence-based treatment guidelines. METHODS: To determine 
      outcomes of MCC patients and assess the role of radiation in treatment, we 
      performed a retrospective chart review of patients treated for MCC between 2006 
      and 2016 at a single high-volume academic medical center. The primary outcome was 
      overall survival (OS) for the entire population and for those populations 
      receiving specific therapies. RESULTS: Forty-two patients were evaluable. OS for 
      all patients was not reached since most remain alive at time of analysis. OS for 
      the American Joint Committee on Cancer (AJCC) stage I was not reached. OS for 
      stages II, III, and IV was 37.3 months (6.8, -), 49.5 months (14.2, 49.5), and 
      14.5 months (10.8, -), respectively. OS could not be reached in the high 
      radiotherapy (RT) dose group (biologically equivalent dose [BED] >/= 60) and was 
      49.5 months (10.8, -) in the low-dose group (BED < 60). For surgical margin 
      status, OS was 14.9158 months (6.8008, -) for positive margins and 37.3 months 
      (10.8, -) for negative margins. CONCLUSIONS: No conclusive findings for OS were 
      identified; however, trends for improved OS were associated with lower AJCC 
      staging, negative surgical margins, and high RT doses.
CI  - (c) 2021 the International Society of Dermatology.
FAU - Nguyen, My-Lien
AU  - Nguyen ML
AD  - Department of Radiation Oncology, University of Oklahoma Health Sciences Center, 
      Oklahoma City, OK, USA.
FAU - Mohammad-Zadeh, Ana
AU  - Mohammad-Zadeh A
AD  - College of Medicine, University of Oklahoma Health Sciences Center, Oklahoma 
      City, OK, USA.
FAU - Krempl, Greg
AU  - Krempl G
AD  - Department of Otorhinolaryngology, University of Oklahoma Health Sciences Center, 
      Oklahoma City, OK, USA.
AD  - Stephenson Cancer Center, University of Oklahoma Health Sciences Center, Oklahoma 
      City, OK, USA.
FAU - Razaq, Mohammad
AU  - Razaq M
AD  - Stephenson Cancer Center, University of Oklahoma Health Sciences Center, Oklahoma 
      City, OK, USA.
AD  - Department of Internal Medicine, Hematology/Oncology Section, University of 
      Oklahoma Health Sciences Center, Oklahoma City, OK, USA.
FAU - Collins, Lindsey
AU  - Collins L
AD  - Department of Dermatology, University of Oklahoma Health Sciences Center, 
      Oklahoma City, OK, USA.
FAU - Zahoor, Talal
AU  - Zahoor T
AD  - Department of Dermatology, University of Oklahoma Health Sciences Center, 
      Oklahoma City, OK, USA.
FAU - Zhao, Daniel
AU  - Zhao D
AD  - Stephenson Cancer Center, University of Oklahoma Health Sciences Center, Oklahoma 
      City, OK, USA.
AD  - Department of Biostatistics and Epidemiology, Hudson College of Public Health, 
      University of Oklahoma Health Sciences Center, Oklahoma City, OK, USA.
FAU - Henson, Christina
AU  - Henson C
AUID- ORCID: 0000-0002-5419-4125
AD  - Department of Radiation Oncology, University of Oklahoma Health Sciences Center, 
      Oklahoma City, OK, USA.
AD  - Stephenson Cancer Center, University of Oklahoma Health Sciences Center, Oklahoma 
      City, OK, USA.
LA  - eng
GR  - P30CA225520/National Cancer Institute Cancer Center/
GR  - University of Oklahoma Stephenson Cancer Center/
GR  - P30 CA225520/CA/NCI NIH HHS/United States
GR  - Oklahoma Tobacco Settlement Endowment Trust/
GR  - Biostatistics and Research Design Shared Resource/
PT  - Journal Article
DEP - 20210720
PL  - England
TA  - Int J Dermatol
JT  - International journal of dermatology
JID - 0243704
SB  - IM
MH  - *Carcinoma, Merkel Cell/radiotherapy
MH  - Humans
MH  - Margins of Excision
MH  - Neoplasm Staging
MH  - Radiotherapy, Adjuvant
MH  - Retrospective Studies
MH  - *Skin Neoplasms/radiotherapy
MH  - Treatment Outcome
PMC - PMC8770723
MID - NIHMS1716511
COIS- Conflicts of Interest: None Declared
EDAT- 2021/07/22 06:00
MHDA- 2022/04/22 06:00
PMCR- 2023/05/01
CRDT- 2021/07/21 13:08
PHST- 2021/04/21 00:00 [revised]
PHST- 2021/01/29 00:00 [received]
PHST- 2021/06/16 00:00 [accepted]
PHST- 2021/07/22 06:00 [pubmed]
PHST- 2022/04/22 06:00 [medline]
PHST- 2021/07/21 13:08 [entrez]
PHST- 2023/05/01 00:00 [pmc-release]
AID - 10.1111/ijd.15759 [doi]
PST - ppublish
SO  - Int J Dermatol. 2022 May;61(5):558-563. doi: 10.1111/ijd.15759. Epub 2021 Jul 20.